Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors-Reference-Cited by-同舟云学术

Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors

Published:2018-05 Issue:38 Volume: Page:292-299
ISSN:1548-8748
Container-title:American Society of Clinical Oncology Educational Book
language:en
Short-container-title:American Society of Clinical Oncology Educational Book

Author:

Raj Nitya¹,Fazio Nicola¹,Strosberg Jonathan¹

Affiliation:

1. From the Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL.

Abstract

In recent years, there have been important scientific advances in the biologic characterization of neuroendocrine neoplasms and in their treatment. This review will describe these scientific advances, the evolving systemic treatment approaches, and important topics to be addressed in future research.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

General Medicine

Link

https://ascopubs.org/doi/pdfdirect/10.1200/EDBK_200893

Reference79 articles.

1. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

2. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

3. Everolimus for Advanced Pancreatic Neuroendocrine Tumors

4. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

5. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review;Chinese Clinical Oncology;2023-12

2. Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors;Future Oncology;2023-10

3. NET G3 vs NEC: p53 and Rb1 Immunolabeling in High-grade Gastrointestinal Neuroendocrine Neoplasms - Is It Enough for the Differential Diagnosis?;Journal of Gastrointestinal and Liver Diseases;2023-06-22

4. HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors;Frontiers in Endocrinology;2023-01-20

5. Neuroendocrine Neoplasm Imaging and Image-Guided Therapies;Multimodality Imaging and Intervention in Oncology;2023